Literature DB >> 164893

Iodohexestrols. II. Characterization of the binding and estrogenic activity of iodinated hexestrol derivatives, in vitro and in vivo.

J A Katzenellenbogen, H M Hsiung, K E Carlson, W L McGuire, R J Kraay, B S Katzenellenbogen.   

Abstract

The affinity of ortho-iodinated hexestrols for the estrogen binding protein from rat uterus, determined by competitive binding assay, decreases with progressive iodine substitution; 3-iodohexestrol (I-Hex) has a binding affinity 42% that of estradiol. Analysis of [3-H]-I-Hex binding in rat uterine cytosol by sucrose density gradient centrifugation shows both an estrogen-specific binding component (8 S) and a more abundant component (4 S) that is not estrogen specific. Scatchard analysis indicates that this latter binding is of high affinity (Kd equals to 3.7-8.3 times 10- minus-9 M) but is not uterine specific. Polyacrylamide gel electrophoresis shows that most of the [3-H]-I-Hex binding activity in serum and uterine cytosol is distinct from and anodic to the principal protein component (albumin), and that is comigrates with [14-C]thyroxine binding activity. In in vitro incubation of rat uteri, I-Hex can block the specific uptake of [3-H]estradiol into the nuclear fraction; it itself causes a translocation of estrogen-specific binding capacity (as measured by exchange) from cytoplasm to nuclei, and can induce the synthesis of an estrogen-specific uterine protein, all under conditions where it is not metabolically deiodinated to hexestrol. The uterotrophic activities of the iodohexestrols are in most cases comparable to that expected on the basis of their competitive binding affinities. However, selective, estrogen-specific uptake of [3-H]-I-Hex into rat uterus, either in vitro or in vivo, cannot be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 164893     DOI: 10.1021/bi00679a029

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

Review 1.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Targeted functional imaging in breast cancer.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

3.  Interaction of 16 alpha-[125I]iodo-estradiol with estrogen receptor and other steroid-binding proteins.

Authors:  R B Hochberg; W Rosner
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

4.  Dose-dependent change in tissue uptake of 17 beta-(16 alpha-[125I]iodo)-estradiol in female rats: application to external imaging of mammary carcinoma.

Authors:  S Noguchi; H Koyama; S Nakano
Journal:  Eur J Nucl Med       Date:  1984

5.  The uptake of radioiodinated 5 alpha-dihydrotestosterone by the prostate of intact and castrated rats.

Authors:  M Tarle; R Padovan; S Spaventi
Journal:  Eur J Nucl Med       Date:  1981-02

Review 6.  PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.

Authors:  John A Katzenellenbogen
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

Review 7.  The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors:  John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2020-02-22       Impact factor: 2.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.